Shots:

• Charles River to acquire HemaCare in all cash transactions at $25.40 /share- making a total deal value $380M with a premium of 33% to HemaCare’s volume-weighted average stock price over the last 60 trading days. The transaction is expected to be completed in Q1’20
• The focus of the acquisition is to expand Charles River’s capabilities in the emerging- high-growth cell therapy market; to establish cell therapy solution from discovery via commercialization which will accelerate client retention and to provide a compelling value proposition for both clients and shareholders
• The addition of HemaCare’s cell therapy products and services to Charles River’s integrated- early-stage solutions will form a unique- go-to partner for clients to work with Charles River across a cell therapy portfolio

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: HemaCare